Imperial College London spin-out Circassia completes Phase II trials into grass allergy treatment.

Circassia, a life sciences spin-out of Imperial College London, has completed Phase II trials into its hay fever treatment.

The UK-based company found that its grass allergy treatment for hay fever sufferers delivered significantly improved allergy symptoms over the pollen period, compared to a control group on placebos.

The life sciences firm, which also developing treatments for immune responses to cats and dust mites, has raised £105m ($178m) since founding in 1998. Among its backers are Imperial College London’s tech…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?